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Abstract     
Research is a tertiary priority in the EHR, where the priorities are patient care 
and billing. Because of this, the data is not standardized or formatted in a manner 
easily adapted to machine learning approaches. Data may be missing for a large 
variety of reasons ranging from individual input styles to differences in clinical de-
cision making, for example, which lab tests to issue. Few patients are annotated at 
a research quality, limiting sample size and presenting a moving gold standard. Pa-
tient progression over time is key to understanding many diseases but many ma-
chine learning algorithms require a snapshot, at a single time point, to create a usa-
ble vector form. Furthermore, algorithms that produce black box results do not 
provide the interpretability required for clinical adoption. This chapter discusses 
these challenges and others in applying machine learning techniques to the struc-
tured EHR (i.e. Patient Demographics, Family History, Medication Information, 
Vital Signs, Laboratory Tests, Genetic Testing). It does not cover feature extraction 
from additional sources such as imaging data or free text patient notes but the ap-
proaches discussed can include features extracted from these sources. 
 
Keywords: Missing data, semi-supervised machine learning, longitudinal model-
ing, machine learning interpretability 
 
1.1   Introduction  
Precision medicine has the potential to substantially change the way patients are 
treated in many facets of health care. Precision medicine is the idea of delivering 
personalized treatment and prevention strategies by considering the holistic patient, 
including their genetics, environment, and lifestyle (Collins and Varmus 2010). Ma-
chine learning using structured clinical data will likely play a large role in the suc-
cess or failure of precision medicine. Specifically, machine learning using structure 
data can help in finding associations between a patient’s genotype and phenotype, 
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identifying similar patients and predicting the efficacy of different clinical treatment 
strategies on a personalized level. 
The amount of digital data collected in the clinic has rapidly expanded, the first 
EHRs are now more than 20 years old. The United States federal government man-
dated meaningful use of EHRs by 2014.  According to the American Hospital As-
sociation, by 2015, 96% of acute care hospitals had implemented a certified EHR . 
Correspondingly, several top research institutions across the country have estab-
lished departments or institutes in biomedical informatics using the EHR as a major 
data source in the past 5 years. 
Smartphones, wearable devices and in-clinic diagnostic tools offer the ability to 
stream accurate measurements in real time. AliveCor received FDA approval in 
2012 for its iPhone-based heart monitor using machine learning to detect Atrial Fi-
brillation in seconds. Billions of dollars in venture capital are currently being in-
vested in companies, such as Grail, Foundation Medicine, and Guardant health, 
promising less invasive biopsies, or liquid biopsies, using machine learning to clas-
sify patients from circulating tumor cells in the bloodstream. Preventative wellness 
clinics, such as Forward, are emerging to characterize and track what it means to be 
healthy.  
These are only a few examples of the many opportunities centered on patient 
data. Data for both evidence-based clinical decision making and computational re-
search is becoming increasingly available and we must now develop new methods 
to preprocess and analyze this data at a matching rate. 
  
1.2   Uses   of   Machine   Learning   for   Structured  
Clinical  Data  
Each time a patient interacts with a health system, actions, notes, and measure-
ments are recorded in the EHR. This wealth of data has made the EHR the primary 
source of structure clinical data. Three popular research applications of EHR data 
are: 
 
1.) Patient clustering to identify similar cases. 
2.) Electronic phenotyping for genetic studies. 
3.) Advising clinical treatment strategies. 
 
These tasks can be performed using machine learning, but each task requires 
careful preprocessing of data and appropriate phrasing of the problem to utilize tra-
ditional machine learning methods. The nature of EHR data places emphasis on 
unsupervised clustering and semi-supervised classification. In this section, we dis-
cuss these common tasks and show examples where researchers have utilized ma-
chine learning effectively to guide discovery. There exist many great resources for 
understanding machine learning approaches as applied to general problems (Bishop 
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2006). We concentrate on how to position relevant clinical questions and the chal-
lenges specific to the EHR that need to be solved in order to apply these powerful 
techniques.  
1.2.1.   Patient/Disease  Stratification  
As we learn more about the mechanisms and etiology of a disease, our diagnoses 
can become more precise, leading to the creation of disease subtypes. Historically, 
cancers were diagnosed based on their occurrence location and their reaction to dif-
ferent treatments. As the mechanisms of cancer are better understood, they are fur-
ther categorized by their physiological nature. The progression of subtypes in lung 
cancer illustrates the increases in resolution over time for a previously poorly de-
fined disease (Kreybe L. 1962). Beginning with a single diagnosis based on occur-
rence in the lung, it was later differentiated as small cell lung cancer and non-small 
cell lung cancer (Mountain 1997; West et al. 2012). Non-small cell lung cancer was 
then broken up into squamous cell carcinoma, adenocarcinoma, and large cell car-
cinoma. Today these subtypes continue to be broken up based on the genetic loca-
tions and pathways of associated risk variants.  
What happens when physiological differences cannot easily be used to subtype 
disease? This is true with several metabolic disorders, for example, metabolic syn-
drome has been redefined numerous times. It is associated with a wide range of 
comorbidities and presents in a clinically heterogeneous manner. These comorbid-
ities, including coronary heart disease, diabetes, and stroke, represent an oversized 
risk to public health and increasingly unwieldy burden on the health care system. 
Despite this, metabolic syndrome’s predictive value for cardiovascular events, dis-
ease prediction and progression is disputed and may not outperform the individual 
components it’s made up of (Shin et al. 2013). While the concept of identifying 
patients at high risk of developing diseases such as heart disease and diabetes for 
early intervention is an important one, metabolic syndrome in its current form fails 
to do this effectively.  
Li et al. demonstrated the ability to identify disease subtypes of patients with a 
metabolic disorder, type 2 diabetes (Li et al. 2015). To do this they performed a 
topological analysis of 11,210 patients with type 2 diabetes at Mount Sinai Medical 
Center in New York. This topological analysis constructed a network of patients by 
connecting those most similar to each other. Using this they found three unique 
subtypes. Subtype 1 demonstrated the traditional observations of type 2 diabetes, 
hyperglycemia, obesity, and eye and kidney diseases. Subtype 2’s main comorbidity 
was cancer, and subtype 3’s unique comorbidities were neurological diseases. These 
subtypes are likely enriched for etiological differences; the disease likely operates 
differently in someone who develops cancer than someone who develops kidney 
disease. By developing a machine learning classifier to identify which subtype a 
patient is in as early as possible, clinicians may be able personalize treatment to 
reduce the odds of developing these more serious comorbidities. 
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Multiple sclerosis (MS) illustrates an additional area machine learning for dis-
ease stratification could be particularly useful. Multiple sclerosis was traditionally 
subtyped into Relapsing-Remitting MS and Progressive MS. In 2014, it was recom-
mended that these subtypes be further divided into six total subtypes (Lublin et al. 
2014). Unfortunately, the current strategies for determining subtype and thus treat-
ment strategy require looking at the progression of the disease. This is essentially a 
retrospective diagnosis and means personalized treatment plans cannot be started 
until progression has been observed. Could unsupervised clustering be used to iden-
tify subtypes earlier on?   
1.2.2.   Electronic  phenotypes  for  Genetic  Associations  
Genetic associations examine whether a genetic variant is associated with a spe-
cific trait (Figure 1). This specific trait, a phenotype, can be a moving target when 
dealing with the complexity of human disease. The trait is often a human defined 
disease. Those with the disease are labeled the case and those without the disease 
are considered controls. Early genetic associations using the electronic health record 
were performed with raw International Classification of Diseases (ICD) codes. ICD 
codes are recorded by physicians when diagnosing a patient with a condition, and 
are used to ensure proper billing and insurance reimbursement. ICD codes are pub-
lished and updated by the World Health Organization and are primarily used for 
clinical billing purposes. Despite ICD-10 being initially published in 1994, ICD-9 
codes are still commonly used in both clinical and research settings.  
 
Figure 1. In this example, the guanine (G) nucleotide is more common in the 
cases than the cytosine nucleotide. 
 
While ICD codes provide a clear, discrete endpoint for genetic associations, the 
use of billing codes can introduce unintentional biases to analyses. An ICD code 
may be added to an EHR in order to issue and receive insurance reimbursement for 
a test to screen for the disease the ICD code represents. In this case, not only is the 
timing of diagnosis difficult to determine, but solely looking at the ICD codes for a 
patient is likely to introduce false positives. In addition, certain ICD codes are more 
Single Nucleotide 
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C
5 
easily reimbursed than others. When a clinician determines that a patient requires a 
treatment or test to increase their odds of a successful outcome, the clinician is in-
centivized to choose the ICD code most likely to allow them to effectively treat their 
patient.  
Phenotype algorithms can be developed using the structured EHR to leverage 
both ICD codes and the rest of the of a patient’s record. The eMERGE project is a 
national network which has deployed phenotype algorithms for over 40 diseases, 
over 500,000 EHRs and 55,000 patients with genetic data. Many of the phenotype 
algorithms are simple rules-based systems, for example: Type 2 Diabetes (Figure 
2). 
 
6  
Figure 2. Phenotype Algorithms for Type 2 Diabetes Mellitus.  A.) Case selection 
from the EHR. B.) Control Selection from the EHR. Adapted from: (Khardori 2014) 
 
An approach to study phenotype-genotype associations from the EHR are Phe-
nome-wide association studies or PheWAS (Denny et al. 2010). PheWAS use EHRs 
to define a phenome that can be linked back to individual genetic variants. The ap-
proach can discover gene-disease associations while identifying pleiotropic effects 
of individual SNPs. PheWAS generally uses the ICD9 codes to construct a pheno-
type. While primarily used for billing, these codes provide a set of discrete variables 
that can represent many phenotypes for a patient at the same time, providing greater 
resolution. Besides the repurposing of billing codes, a major challenge of PheWAS 
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is in understanding the functional mechanisms at work behind GWAS SNP 
matches. Stratification by the 4,841 different codes creates wide data, presenting 
statistical challenges in achieving adequate power. This challenge of achieving ad-
equate power will be exacerbated by the transition to ICD10, with less historical 
data built up and the potential for over 16,000 codes. Continuing to increase open 
data access will allow researchers to utilize a more accurate phenotypic representa-
tion while lessening the burden of statistical challenges. Coding systems, unlike pa-
tient notes or genomic data should be easier to anonymize, aggregate, and distribute. 
Because ICD billing codes can be biased, as evidenced by phenotype algorithms 
having multiple steps to catch errors for both case and control status, using billing 
codes alone may cause misclassification of phenotypes. The misclassification of 
phenotypes substantially reduces the power to detect linkage in case-control studies. 
With 1% phenotypic misclassification up to 10% of the power is lost, and with 5% 
phenotypic misclassification, the power is reduced by approximately two-thirds 
(Gordon et al. 2004; Buyske et al. 2009; Manchia et al. 2013). Misclassification can 
occur for a variety of reasons including misdiagnosis/clinical error, clerical error, 
or lack of scientific knowledge about the disease in question. 
Labbe et al. showed increased linkage by clustering lifetime symptoms in schiz-
ophrenia and bipolar disease to form more homogenous phenotypes. Separating 
cases by the symptoms of psychiatric diseases compensates for the inability to sub-
type these diseases by physical properties (Labbe et al. 2012). This is important due 
to the deficit of physiological understanding for these diseases. Labbe et al. also 
included familial information to understand the heritability of these diseases. When 
looking at subtypes that show a strong familial aggregation they observed higher 
linkage scores. By looking at ancestral histories for subtypes, the expected herita-
bility could be better estimated resulting in a reduction of “missing heritability.”  
Phenotypic subtyping was also used successfully in the analysis of genetic vari-
ants responsible for the severe development regression and stereotypical hand 
movements of Rett syndrome. Causal mutations were found in the FOXG1 and 
MECP2 genes and deletions at the 22q11.2 locus (Chaste et al. 2015).  
Each of these examples point towards the promise of using machine learning to 
cluster patients based on their EHRs to identify disease subtypes or more homoge-
nous groups of patients for use in association studies. 
1.2.3.   Clinical  Recommendations    
The availability of data and advances in biomedical informatics have helped to 
make medicine increasingly evidence based and in some cases entirely data driven. 
Clinicians and researchers now have the ability to leverage millions of data points 
when designing and determining treatment best practices. The New England Journal 
of Medicine recently held the SPRINT data analysis to “use the data underlying a 
recent article to identify a novel clinical finding that advances medical science.”  
The original clinical trial sought to see whether intensive management of systolic 
blood pressure (<120 mm Hg) was more effective than standard management (<140 
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mm Hg). The original trial was stopped early due to the success of the intensive 
management strategy in reducing cardiovascular events. The data from the trial was 
released as a challenge where teams used machine learning approaches (primarily 
rules based) to provide personalized recommendations. 
More personalized treatment strategies are a popular use of machine learning in 
the EHR. This can be driven by genomics (pharmacogenomics), or simply by sub 
setting patients based of attributes (race, BMI, etc.). Wiley et al. demonstrate the 
importance of training an algorithm on a population similar to the application pop-
ulation (Wiley et al. 2016). In their case it was necessary to extract the perecent 
African ancestry from the genome instead of self reported race in order to improve 
the model fit. 
Due to the inherent risk of adjusting clinical treatment strategies, many of the 
early applications of machine learning in health systems have been seen in academic 
research (retrospective analysis, drug development, pharmacogenomics) and for 
things like resource usage. For example, how likely is a patient coming into the ER 
to need an ICU bed? Increasingly machine learning methods are likely to be applied 
to clinical decisions including providing prognosis information for shared decision 
making strategies. Deep learning, in particular, is becoming an increasingly tool for 
drug discovery and development (Ching 2017).  
 
1.3   Challenges  of  using  Machine  Learning  in  the  
Structured  EHR  
1.3.1.   Limited  “gold-­standards”  
Large institutions and health care systems can have EHRs containing millions of 
patients and billions of measurements. Despite the size of these data, electronic phe-
notyping requires a gold standard to validate accuracy. This gold standard often 
requires time consuming, manual clinician review and is thus expensive.  
In addition, the selection of cases and controls can unintentionally create biases 
in downstream algorithms and analyses. It is often easiest to select the most severe 
cases and the healthiest controls. In these circumstances researchers can have the 
greatest confidence they are accurately selecting a true case or control. Unfortu-
nately, this creates a biased training set where it is difficult to differentiate between 
less severe cases and less healthy controls. Figure 3 shows an illustration of a sim-
ulated dataset where the first two principal components happen to represent the de-
gree of the case phenotype. If the most severe cases are selected, a classifier trained 
to distinguish between cases and controls is unlikely to generalize well. If less se-
vere cases are chosen, there may be issues with mislabeled cases. An example of 
another bias can be seen in the Type 2 Diabetes Mellitus algorithm, controls must 
have at least 1 glucose measurement (Figure 2B). For a young patient, this means 
that a clinician must have had reason to suspect that the patient’s glucose could be 
abnormal and thus could bias controls to patients who “look” like they are at a high 
risk for developing Type 2 Diabetes. 
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Figure 3. Simulated disease severity plot where the 2 principal components stratify 
patients according to severity.  
 
Because patients move between health systems, a patient may not be diagnosed 
in the system they are treated in and may only have a partial history. Some methods 
for controlling for incomplete histories can result in smaller sample sizes. It is com-
mon to include only patients who have a visit in the system prior to the diagnosis of 
the phenotype of interest. While this can help to determine the diagnosis date for a 
disease, it excludes anyone who was diagnosed on their first visit to a particular 
health system. 
Healthy
Sick
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1.3.2.   Missing  Data  
The average patient is unlikely to have measurements for the clear majority of 
fields in the EHR. It does not make sense logistically or economically to administer 
every test to a seemingly healthy patient. There are three primary types of missing 
data:  
 
1.) Missing Completely at Random (MCAR) – when data is missing in a com-
pletely unrelated way to the values of both the observed and the unobserved data. 
2.) Missing at Random (MAR) – when the data is missing based on the observed 
data, when other fields in the EHR indicate whether the value will be present or 
absent. 
3.) Missing Not at Random (MNAR) – when the data is missing based on the 
values of the unobserved data  
 
Figure 4 shows the ability to use a random forest to predict whether a lab value 
will be present or absent based on other lab values. Unsurprisingly data that is 
MCAR cannot be predicted (Figure 4A), and data that is either MAR or MNAR 
(Figure 4B, 4C) can be predicted with an accuracy significantly greater than ran-
dom. In practice, most missing data in the EHR tends to be of the MAR variety. 
Clinicians must decide which measurements are relevant and fiscally responsible, 
irrelevant tests are wasteful and it does not make sense to subject patients to unnec-
essary discomfort. The clinician is making these decisions based on the observations 
they make, so when data is missing it is related to the observed data.  
 
 
Figure 4. A.) Data that is missing completely at random cannot be predicted. B & 
C.)  Data that is missing at random and missing not at random can be predicted. (To 
appear) 
 
MCAR data is less likely to present issues to downstream analyses than data that 
is either MAR or MNAR, but if not handled correctly all three types of missing data 
can introduce unintentional biases to all sorts of downstream analyses including 
machine learning. Machine learning algorithms often expect a complete matrix as 
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input and are not designed to handle null values. This often leads to researchers 
performing one of three options:  
 
1.) Perform feature selection of relevant features and use only complete cases, or 
patients that have values for all features.  
2.) Modify the algorithm to accept null inputs (often by ignoring them) or 
3.) Perform imputation to predict what the value for a feature would be.  
 
Each of these options have several pros and cons and can have unintended effects 
on machine learning. When performing complete case analysis after feature selec-
tion, the features included can lead to including either more severe cases or cases 
that were harder to diagnose. Imagine a disease that is diagnosed by a laboratory 
measurement where values over 10 conclusively indicate you have the disease but 
values between 8 and 10 require an additional test. If the additional test is included 
in the features selected, the complete cases are now only the patients that were 
harder to diagnose. When modifying an algorithm to accept null inputs, the re-
searcher needs to be careful that the algorithm does not disproportionately learn to 
depend on patients that have all of the measurements or only the most complete 
measurements. If the algorithm relies on patients with all of the measurements, 
many of the same issues that arise in complete case analysis repeat. If the algorithm 
learns to ignore rare measurements it can miss signal. For example, in an analysis 
of different treatment options, say 40 of 10,000 patients suffered a fairly rare but 
severe adverse event. Without careful monitoring the algorithm may not place 
enough importance on this feature despite the fact this outcome is disproportion-
ately important.  
 
 
Figure 5. Comparison between spike in accuracy and variation between imputation 
runs. 
 
Imputation can be effective in the EHR because many missing values can be 
inferred by omission and just knowing whether a value was present or absent can 
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be useful. If a patient has never had a chest x-ray, it is unlikely that their physician 
suspects a broken rib cage. This information can be provided to downstream ma-
chine learning algorithms by performing imputation. It is, however, very important 
to carefully analyze the results of imputation. Oftentimes much can be learned 
simply by looking at which methods are the most accurate. Direct accuracy can be 
measured by spiking in missing values to replace known values, imputing these 
spiked-in values and measuring their difference from the real values. Despite this 
direct accuracy should only be used as a benchmark, and it is important to analyze 
the effect of imputation on the downstream analyses you are performing (Figure 5).  
For example, mean imputation may perform strongly in an analysis using spiked-
in missingness but remove all variance from the imputed values for a feature (Figure 
5C). Other evaluation criteria, such as, comparing the variance between imputed 
values of different imputation runs and the difference between imputed values and 
real values. Ideally these values would be highly correlated in order to maintain the 
variance structure. Popular imputation methods for EHRs include K-Nearest Neigh-
bors, Singular Value Decomposition and Multiple Imputation by Chained Equa-
tions. 
All three of these strategies for handling missing data may introduce bias when 
performing EHR-based analyses. It is important to consider potential effects and 
ideally to utilize multiple strategies and examine the differences. 
1.3.3.   Privacy,  Reproducibility  and  Data  Sharing  
Patient privacy needs to be a focus of any secondary use of EHRs. Because a 
patients EHR is ‘de-identified’ does not mean that it is anonymous. Latanya 
Sweeney demonstrated this emphatically when the Massachusetts Group Insurance 
Commission released de-identified data on state employees (Shaw 2009). These 
records included each hospital visit and Sweeney was able to re-identify several 
patients including the former Governor of Massachusetts. Sweeney was able to do 
this from his birth date, zip code and sex alone, and to prove a point mailed the 
Governor a copy of his personal records. The task of re-identification has been 
shown possible in several other cases where data holders attempted to share their 
data, including the Netflix challenge. Narayana and Shmatikov were able to de-
anonymize users in the Netflix challenge by linking their viewing histories with 
popular movie review sites. For users who had rated more than 6 movies, they were 
able to do this with greater than 90% accuracy (Narayanan and Shmatikov 2008). 
This, in part, led to Netflix canceling the second iteration of its popular recommen-
dation contest following a privacy lawsuit. 
Caution needs to be taken even when the actual data is not released. Deep learn-
ing models can have many millions of parameters, allowing adversaries to perform 
membership inference attacks in order to determine whether a user was a member 
of the study or not. Shokri et al. (Shokri et al. 2016)) demonstrate greater than 90% 
precision even with 30,000 examples in the training set. They do this by examining 
the trained parameters of a deep neural network trained on the CIFAR-100 dataset. 
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Even without the model, enterprising adversaries performed membership inference 
attacks with only black-box access to the target model through an API. Shokri et al. 
again demonstrated this on various purchase history datasets made available 
through Amazon and Google APIs.  
One approach to adding privacy protection is called “Differential Privacy” 
(McSherry and Talwar 2007). Differential Privacy is a robust, meaningful and math-
ematical rigorous definition of privacy which operates under the knowledge that 
data cannot be fully anonymized and remain useful. If you remove all of the signal 
in a dataset to anonymize, machine learning methods are fruitless. If you keep any 
signal at all, there is a chance an adversary will able to discover information about 
the members of the dataset. The goal of differential privacy is to find a balance 
between an acceptable risk, the privacy budget, and usefulness of the data. It at-
tempts to minimize the likelihood an adversary can perform a membership inference 
attack to determine if a subject is in a dataset. It works by adding a plausible denia-
bility of any outcome by inserting random noise into the information made availa-
ble. If balanced, meaningful answers can be interrogated from the data while greatly 
reducing the risk that any member of a study is harmed by de-identification. A clas-
sic example and simple way to think about differential privacy is to imagine a study 
where participants are told to answer a question. Before answering the question they 
flip a coin, if the coin lands heads, they give the real answer, the truth. If the coin 
lands tails, they answer randomly by flipping an additional coin and responding yes 
if it lands heads and no if it lands tails.  
Simmons et al. used a variant of differential privacy to enable privacy preserving 
genome wide association studies even when there is significant population stratifi-
cation. Genomic data has a high dimensionality and relatively low signal to noise 
ratio making de-identification or other attempts at masking individual records im-
practical. They demonstrate the ability to allow users to query summary statistics 
while minimizing privacy risks. This is a particularly interesting application be-
cause while genome sequencing prices have rapidly decreased, the combined costs 
of recruitment and sequencing are a major barrier to this type of research.  
Beaulieu-Jones et al. recently showed the ability to train deep neural networks 
under differential privacy to generate synthetic data that closely resembles the 
SPRINT clinical trial data (Beaulieu-Jones et al. 2017). This method allows for in-
creased sharing of valuable, difficult to obtain datasets. Differential privacy is a 
rapidly growing area, we suggest “The Algorithmic Foundations of Differential Pri-
vacy” (Dwork and Roth 2013) as a starting point if interested in implementing dif-
ferential privacy. 
Privacy challenges can make sharing data prohibitively difficult. This in turn 
presents challenges in reproducing work from other researchers. Even if source code 
is shared, researchers attempting to reproduce original research generally can only 
compare final results. This means that even if a protocol of a paper is well written 
and described, if it has 100 steps, a researcher attempting to reproduce cannot be 
sure where their results diverged. Because of this challenge we strongly advocate 
publishing intermediate results. This can help narrow down divergences to a few 
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steps, was it the data? The preprocessing? The actual analysis? The plotting into 
charts? One way to release intermediate results without adding a large amount of 
additional work is to use continuous integration to run the analysis and export the 
log file (Beaulieu-Jones and Greene 2017).  
1.3.4.   Longitudinal  Data  
A key attribute and potential strength of EHRs is the ability to track the way a 
patient progresses over time. Early moving caregivers such as Geisinger Health Sys-
tem implemented initial EHRs over twenty years ago but fully utilizing this longi-
tudinal presents challenges to researchers.  
Longitudinal EHR data are often irregular time series. Measurements are rec-
orded at irregular times, can be mixed type (continuous, ordinal, categorical), re-
quire feature extraction (images, free text). It is common for researchers to take a 
single time point (i.e. current time, set time after diagnosis etc.) and use this as the 
single end point or label for machine learning analyses. This can be problematic 
when patients have arrived at that point through very different routes. For example, 
if using a systolic blood pressure as an end point, one patient may be on an intensive 
blood pressure management protocol while another with the same blood pressure 
may have never taken medication. In the SPRINT clinical trial there were patients 
on as many as seven medications to manage blood pressure (Group 2015), if un-
medicated these patients would almost definitely have significantly higher meas-
urements. One method researchers use to remediate this issue is to derive statistics 
to represent the time series, such as taking the median value. This can be insufficient 
when the way clinicians choose to observe and treat patients based on data either 
not recorded in the electronic health record, in the unstructured data or in fields not 
selected for inclusion can also bias the labels. For example, if patient A has a single 
normal white blood cell count, and patient B has had a monthly count every month 
for the past 5 years. A clinician could have been checking to see if patient A showed 
an increased white blood cell count after a surgery suspecting a possible infection. 
In contrast, the repeated measurements for patient B indicate the clinician may have 
a reason to believe patient B is immunocompromised or may become immunocom-
promised due to a virus or adverse reaction to a medication and is using the white 
blood cell count to monitor this. Despite the patients having relatively equal white 
blood cell counts, using this single value as a label is clearly inadequate to represent 
the complete state of the patient. For this specific case deriving a panel of statistics 
including features such as the count and variance of the measurement could help to 
better represent the current state of a patient. Recent work takes this further to cal-
culate disease and patient trajectories by generating networks of the way a patient 
or disease progresses over time. Jensen et al. demonstrated this using 6.2 million 
patients from Danish National Patient Registry to cluster patients based on time 
dependent disease diagnoses (Jensen et al. 2014). These disease diagnoses were ex-
tracted from patterns of ICD-9 codes on patient’s EHRs. This method creates a vis-
ualization of patient trajectories and allows for analyses of co-morbidities observed 
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in health systems in order to identify important patterns that indicate the potential 
for more severe outcomes. Further work in this field could move beyond billing 
codes in order to allow for increased resolution of patient trajectories. 
 
 
1.4   Future   and   evolving   opportunities   for   Ma-­
chine  Learning  in  the  Structured  EHR  
1.4.1.   Quantitative  Electronic  Phenotyping  
Traditionally, genetic association studies relied on binary outcomes as target 
phenotypes for the association. Quantitative trait loci studies provide the ability to 
measure correlation between DNA variation and a phenotype. Quantitative traits 
occur on a continuum and are driven by multiple genes in conjunction with the en-
vironment. By using clustering and other machine learning techniques, researchers 
can represent disease as quantitative rather than binary values. This has several ad-
vantages. Patients with a common disease that present with different symptoms, 
different levels of effect or different paths of progression can be clustered into ho-
mogenous subgroups with similar patients. These clusters are likely enriched etio-
logically, meaning the reasons the disease is causing each cluster are different. 
Within each cluster or across the entire spectrum of diseases, a phenotype can be 
constructed to better represent how severe of a case a patient has. Diseases where 
using a binary case control status has been effective are likely etiological homoge-
nous, or so disruptive to a particular system that the severity is irrelevant. These 
represent the low hanging fruit, but many diseases present in heterogeneous man-
ners (Cancers, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Alzheimers etc.). 
Fine-tuned quantitative phenotyping could have the ability to resolve homogenous 
subgroups, greatly increasing statistical power and creating a better target for asso-
ciation. 
1.4.2.   Deep   Learning,   Unsupervised   and   Semi-­Supervised  
Learning  Approaches  
Deep Learning has already led to state of the art results in a variety of fields 
including image processing, speech recognition, and gameplay. Many of the early 
“wins” using deep learning and more generally machine learning in the EHR in-
volve applications of algorithms proven successful in other domains. This has been 
particularly true in unstructured EHR data such as images (cancer tumor detection 
etc.) and natural language processing for free text. This is sufficient when EHR 
learning tasks resemble tasks popular among general machine learning researchers 
but long term advances will require specialized algorithms customized to the unique 
challenges presented by EHR-based research. Algorithmic development is only one 
part of the equation. The proper phrasing of problems and preprocessing of data will 
likely have as much if not more importance than algorithmic development. 
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Three of the pioneers of deep learning, Yann Lecun, Yoshua Bengio and Geof-
frey Hinton wrote, “Unsupervised learning had a catalytic effect in reviving interest 
in deep learning, but has since been overshadowed by the successes of purely su-
pervised learning… we expect unsupervised learning to become far more important 
in the longer term” (LeCun et al. 2015). The challenge of collecting labeled data for 
supervised learning in the EHR may be an ideal environment for a reemergence of 
unsupervised and semi-supervised learning approaches. Early examples show that 
deep autoencoders are adept at this task (Beaulieu-Jones and Greene 2016; Miotto 
et al. 2016).  
1.4.3.   Interpretation  and  the  “Right  to  explanation”  
For some clinical decisions, a black box algorithm with high accuracy is suffi-
cient to improve medical care. An algorithm that can more accurately identify a 
tumor in imaging than a human has obvious benefits. For other problems, a black 
box is insufficient, it is unlikely to help researchers understand the physiology or 
etiology of a disease. In this setting, outside of a clinical decision, a less accurate 
but interpretable algorithm may be preferred. In addition, clinicians are likely to be 
skeptical and slower to adopt algorithms whose decisions cannot be rationally ex-
plained. 
Furthermore, in April 2016, the European Union passed a data protection law 
entitled the “General Data Protection Regulation (GDPR) which will begin in 2018. 
The GDPR provides stricter conditions for sensitive data collection and storage, 
including, for example genetic and biometric data. It also sets regulation on privacy 
policies and further formalizes the “right to be forgotten.” Of particular interest to 
the machine learning community is the language prohibiting decisions “based solely 
on automated processing and which produces adverse legal effects concerning, or 
significantly affects, him or her” and provides the right “to obtain an explanation of 
the decision reached after such assessment or to challenge the decision.” It remains 
to be seen how this would be applied and if it will have any effect on the usage of 
artificial intelligence in the clinic but it demonstrates the fact that people want to 
understand how and why a decision affecting their wellbeing is made. Work to cre-
ate high performing algorithms that provide interpretable, explainable decisions is 
increasingly important as clinicians increasingly rely on the aid of artificial intelli-
gence. 
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